title: Is in vitro-acquired resistance to enzalutamide a useful model?
authors.affiliation: Medical Oncology Unit, Department of Clinical Medicine, Federico II University, Naples, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Buonerba
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D009570:Nitriles; D043823:Taxoids; D010669:Phenylthiohydantoin; C552428:cabazitaxel; C540278:enzalutamide
keywords: abiraterone; acquired resistance to the therapy; cabazitaxel; castration-resistant prostate cancer; enzalutamide